Heart Failure

The heart transplant from a genetically modified pig was initially considered a success and represented new hope for Americans requiring transplants.

Dr. Granger discusses the current underuse of these agents and the steps cardiologists need to take to increase prescription rates and uptake for patients.

The University of Colorado expert joins for a 5-part interview on making sense of the boom of new agents and care strategies.

The Yale Associate Chief of Cardiovascular Medicine discusses improved use of available drug classes, as well as the potential approval for omecamtiv mecarbil.

The absolute survival rate observed for US patients with IHCA and COVID-19 was 11.9%.

The expanded indication for the CardioMEMS HF System includes patients with NYHA Class II heart failure and elevated levels of natriuretic peptides.

Severe financial strain was associated with a 61% increase in 180-day mortality risk, compared to patients with no strain.

Higher variability of adiposity indices was associated with significantly increased risk of CVD outcomes in standard of care, but not in the intensive lifestyle intervention group.

Data show atherosclerotic burden was heterogeneous across LDL-C levels and risk is shown to be consistently associated with plaque burden.

The NDA has been assigned standard review with a PDUFA target action date in late November 2022.

Don't Miss a Beat is Practical Cardiology's expert-led podcast. The monthly podcast, which is hosted by Drs. Greene and Vaduganathan, will provide a regular news roundup of the latest evidence and clinical trial insights across cardiovascular, renal, and metabolic diseases.

The TPV system expands transcatheter therapy options for patients with congenital heart valve disease.

Data show the multivariable-adjusted HR for increase in seafood consumption of 1 oz per day and all-cause mortality was 0.84 and for CVD-related mortality was 0.89.

Study data show for each $1,000 decrease in median household income, the number of TAVR procedures performed per 100,000 Medicare beneficiaries was 0.2% lower.

After 1 year, 37% of patients had died and 65% of patients were readmitted to the hospital.

Young smokers in 2017 were more likely to have other comorbid conditions including hypertension, diabetes, and obesity.

The least selected attributes were food and medication restrictions and A1c lowering followed by risk of diabetic ketoacidosis, risk of genital infection, and the avoidance of severe hypoglycemia.

Deepak Bhatt, MD, MPH, discusses the results of a pooled analysis of the SOLOIST and SCORED trials assessing effects of sotagliflozin based on baseline eGFR among patients included in the trials.

Epinephrine before defibrillation was associated with lower odds of survival to discharge, favorable neurological survival, and survival after acute resuscitation

In patients with advanced heart failure, the median NT-proBNP AUC for valsartan was 1.19 compared to an AUC of 1.08 for sacubitril/valsartan.

The American College of Cardiology and American Heart Association guideline provides key highlights into the evaluation and diagnosis of adult patients with chest pain.

In 1774 estimated discharges where a hospital region in the US had been indicated, 35.9% were diagnosed in the West and 32.3% in the South.

Data show the overall risk difference between the first and second doses of BNT162b2 was 1.76 per 100,000 persons.

In the primary endpoint, patients with severe HF had a 20% risk reduction compared to no significant treatment benefit in patients without severe HF.

Proposed new guidelines recommended against low-dose aspirin use for primary prevention of CVD in adults age 60 years or older, citing adverse effects.

A significantly increased risk of hospitalization from pneumonia was observed due to haemophilus influenzae.

Dr. Erickson discussed screening for children prone to sudden cardiac arrest and sudden cardiac death based on an updated AAP policy statement.

Differences in CV risk factors persisted between Black participants and White participants and may be due to social determinants of health.

Data show SGLT2 inhibitor therapy, in comparison to GLP-1 RA therapy, was associated with slightly lower risk for myocardial infarction (MI) or stroke in patients with CVD.